比较生酮饮食中饱和与不饱和脂肪来源对超重且患糖尿病前期或2型糖尿病成人患者心血管、炎症及免疫功能影响的随机对照试验方案(KETO-IM)
KETO-IM是一项在加拿大埃德蒙顿开展的开放标签、单中心、三平行组、优效性随机对照试验,计划纳入175名超重且HbA1c>5.7%的成人,按1:1:1分配至强调饱和脂肪的生酮饮食组、强调不饱和脂肪的生酮饮食组或低脂标准治疗饮食组,干预6个月,主要结局为血浆LDL-C和甘油三酯,次要结局包括糖代谢、炎症和免疫功能,并首次比较生酮饮食对免疫反应的影响。
要点
- KETO-IM试验比较饱和脂肪生酮饮食、不饱和脂肪生酮饮食与低脂标准治疗饮食对心血管代谢风险、炎症及免疫功能的影响。
- 主要结局为血浆LDL-C和甘油三酯,次要结局包括糖代谢、炎症和免疫功能。
- 研究假设为两种生酮饮食组甘油三酯降低幅度大于低脂对照组,且不饱和脂肪生酮饮食组LDL-C降低幅度大于饱和脂肪生酮饮食组。
核心结论
- 该试验将直接比较生酮饮食中不同脂肪来源与低脂标准治疗饮食对男女成人心脏代谢风险、炎症和免疫功能的影响。
- 试验结果可用于指导寻求改善血脂和血糖控制的患者的临床建议,并首次比较生酮饮食对免疫反应的影响。
研究设计与样本
- KETO-IM研究为开放标签、单中心、三平行组、优效性随机对照试验(RCT)。
- 计划纳入年龄18至70岁、体重指数(BMI)>23 kg/m2(亚洲及南亚裔)或>25 kg/m2(非亚洲裔)且糖化血红蛋白(HbA1c)>5.7%的成人,由研究团队从加拿大埃德蒙顿及周边社区招募。
- 共175名参与者按1:1:1比例分配至三组,评估终点为3个月和6个月时与基线比较。
关键数值与推荐
- 主要结局为评估心血管疾病风险的 plasma LDL-C 和甘油三酯(TG)。
- 次要结局包括糖代谢、炎症和免疫功能,其中免疫功能比较是新的重点。
- 研究假设(1):两个生酮饮食组循环甘油三酯(TG)相对低脂标准治疗饮食(LFD)对照组降低更多;(2)与富含饱和脂肪的生酮饮食相比,较高不饱和脂肪摄入可使低密度脂蛋白胆固醇(LDL-C)降低幅度更大。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Among the general public, the ketogenic (KETO) diet is popular for weight loss and may also support glycemic control in people with type 2 diabetes (T2D). Obesity and T2D have both been associated with diminished immune responses, increasing the risk of infection. KETO diets are often high in saturated fats (SFA), which may increase cardiovascular disease (CVD) risk as well as inflammation. Substituting SFA for unsaturated fats (UFA) may improve these outcomes. This study aims to compare lipid measures, glycemia, inflammation, and immune function in people with, or at risk of developing, T2D after following KETO diets emphasizing SFA versus UFA versus a low-fat standard of care diet (LFD) for 6 months. We hypothesize that (1) circulating triglycerides (TG) will be reduced more in the two KETO groups relative to the control LFD and (2) low-density lipoprotein (LDL-C) will be lowered to a greater extent with higher UFA consumption relative to KETO rich in SFA. METHODS: The KETO-IM study is an open-label, single-center, three parallel-arm, superiority, randomized controlled trial (RCT). It will enroll adults aged 18 to 70 years with body mass index (BMI) > 23 kg/m2 (Asian and South Asian), or > 25 kg/m2 (non-Asian) and glycated hemoglobin (HbA1c) > 5.7%, recruited by the study team from the community in Edmonton, Canada and surrounding area. Participants (175 total) will be allocated to three groups in a 1:1:1 ratio with evaluation endpoints at three and six months compared to baseline. The primary outcomes assessing CVD risk, will be plasma LDL-C and TG. Secondary outcomes of the trial include glucose metabolism, inflammation and immune function. Among the secondary outcomes, comparison of immune function will be a novel focus. DISCUSSION: This trial will directly compare the effects of fat sources in a KETO diet to a control LFD on cardiometabolic risk, inflammation and immune function in adults of both sexes. The results of this trial can be used to guide clinical advice to patients seeking to improve lipid and glycemic control while, for the first time, comparing the effects of KETO diets on immune response. TRIAL REGISTRATION: ClinicalTrials.gov, NCT05681468. Registered on 12 December 2022, https://clinicaltrials.gov/study/NCT05681468?titles=keto-im&rank=1 . First enrollment September 18, 2023.
引用
- Fulton JL, Gartke T, Blanco Cervantes P, et al. Protocol for a randomized controlled trial comparing saturated and unsaturated fat sources of a ketogenic diet (KETO-IM) investigating cardiovascular, inflammatory and immune function outcomes in adults living with overweight and prediabetes or type 2 diabetes in Edmonton, Canada. Trials. 2026. PMID: 41673680. doi:10.1186/s13063-026-09501-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。